Basoglu Ozen K, Pelleg Amir, Essilfie-Quaye Sarah, Brindicci Caterina, Barnes Peter J, Kharitonov Sergei A
Section of Airway Disease, National Heart & Lung Institute, Faculty of Medicine, Imperial College, Dovehouse St, London SW3 6LY, UK.
Chest. 2005 Oct;128(4):1905-9. doi: 10.1378/chest.128.4.1905.
Extracellular adenosine 5'-triphosphate (ATP) causes neurogenic bronchoconstriction, inflammation, and coughs, and may play a mechanistic role in obstructive airway diseases. The aims of this study were to determine the effects of inhaled ATP on airway function, and to compare these effects with those of adenosine 5'-monophosphate (AMP).
Prospective, randomized, double-blind study.
Clinical research laboratory of a postgraduate teaching hospital.
The effects of inhaled equimolar doses of ATP and AMP on airway caliber, perception of dyspnea quantified by the Borg score, and other symptoms were determined in 10 nonsmokers (age 41 +/- 3 years) and 10 patients with asthma (age 39 +/- 3 years) [+/- SEM].
None of the healthy nonsmokers responded to ATP or AMP. All the patients with asthma responded to ATP, and 90% responded to AMP. The geometric mean of the provocative dose causing a 20% fall in FEV1 (PD20) of ATP was 48.7 micromol/mL and that of PD20 AMP was 113.5 micromol/mL in responsive asthmatics (p < 0.05). In asthmatic patients, the percentage change in FEV1 caused by ATP was greater than that caused by AMP (deltaFEV1 ATP = 29% vs deltaFEV1 AMP = 22%, p < 0.05). Borg score increased significantly in asthmatics after ATP (from 0.1 to 3.3, p < 0.01) and after AMP (from 0.2 to 2.5, p < 0.01). This increase was also greater after ATP than AMP in asthma (deltaBorg ATP = 3.2 vs deltaBorg AMP = 2.3, p < 0.05). ATP induced cough in 16 subjects (80%), while AMP induced cough in 8 subjects (40%) [p < 0.05]; in addition, more subjects had throat irritation after inhalation of ATP than AMP (p < 0.05).
ATP is a more potent bronchoconstrictor and has greater effects on dyspnea and other symptoms than AMP in asthmatic patients. Therefore, ATP could potentially be used as a bronchoprovocator in the clinical setting.
细胞外三磷酸腺苷(ATP)可引起神经源性支气管收缩、炎症和咳嗽,可能在阻塞性气道疾病中发挥作用。本研究旨在确定吸入ATP对气道功能的影响,并将这些影响与一磷酸腺苷(AMP)的影响进行比较。
前瞻性、随机、双盲研究。
一家研究生教学医院的临床研究实验室。
在10名非吸烟者(年龄41±3岁)和10名哮喘患者(年龄39±3岁)[±标准误]中,测定吸入等摩尔剂量的ATP和AMP对气道管径、用Borg评分量化的呼吸困难感知以及其他症状的影响。
所有健康非吸烟者对ATP或AMP均无反应。所有哮喘患者对ATP有反应,90%对AMP有反应。在有反应的哮喘患者中,使第一秒用力呼气容积(FEV1)下降20%的激发剂量(PD20),ATP的几何平均值为48.7微摩尔/毫升,AMP的几何平均值为113.5微摩尔/毫升(p<0.05)。在哮喘患者中,ATP引起的FEV1百分比变化大于AMP引起的变化(ATP引起的FEV1变化量=29%,AMP引起的FEV1变化量=22%,p<0.05)。哮喘患者吸入ATP后Borg评分显著增加(从0.1增至3.3,p<0.01),吸入AMP后也显著增加(从0.2增至2.5,p<0.01)。在哮喘患者中,吸入ATP后Borg评分的增加也大于吸入AMP后(ATP引起的Borg评分变化量=3.2,AMP引起的Borg评分变化量=2.3,p<0.05)。ATP使16名受试者(80%)诱发咳嗽,而AMP使8名受试者(40%)诱发咳嗽[p<0.05];此外,吸入ATP后咽喉刺激的受试者比吸入AMP后更多(p<0.05)。
在哮喘患者中,ATP是一种更强效的支气管收缩剂,对呼吸困难和其他症状的影响比AMP更大。因此,ATP在临床环境中可能可用作支气管激发剂。